NEURIZON Trademark

Trademark Overview


On Monday, October 28, 2024, a trademark application was filed for NEURIZON with the United States Patent and Trademark Office. The USPTO has given the NEURIZON trademark a serial number of 79410014. The federal status of this trademark filing is NON-FINAL ACTION COUNTED - NOT MAILED as of Monday, April 7, 2025. This trademark is owned by PharmAust Limited. The NEURIZON trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development services; development of pharmaceutical preparations and medicines; research and development services of new pharmaceutical products; consultancy relating to pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical testing; pharmaceutical product evaluation; providing information about the results of clinical trials for pharmaceuticals; biological, clinical and medical research; consultancy relating to research and development in the field of therapeutics; conducting clinical trials; providing information and data relating to medical and veterinary research and development; providing information relating to medical research in the field of veterinary pharmacovigilance; veterinary research; veterinary laboratory services; scientific research for medical purposes in the field of cancerous diseases; drug development services.
neurizon

General Information


Serial Number79410014
Word MarkNEURIZON
Filing DateMonday, October 28, 2024
Status640 - NON-FINAL ACTION COUNTED - NOT MAILED
Status DateMonday, April 7, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Translation of Words in MarkThe wording "NEURIZON" has no meaning in a foreign language
Goods and ServicesPharmaceutical research and development services; development of pharmaceutical preparations and medicines; research and development services of new pharmaceutical products; consultancy relating to pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical testing; pharmaceutical product evaluation; providing information about the results of clinical trials for pharmaceuticals; biological, clinical and medical research; consultancy relating to research and development in the field of therapeutics; conducting clinical trials; providing information and data relating to medical and veterinary research and development; providing information relating to medical research in the field of veterinary pharmacovigilance; veterinary research; veterinary laboratory services; scientific research for medical purposes in the field of cancerous diseases; drug development services.

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, November 21, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNeurizon Therapeutics Limited
Party Type11 - New Owner Before Publication
Legal Entity Type98 - Unknown
AddressAU

Party NamePharmAust Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAU

Trademark Events


Event DateEvent Description
Thursday, November 21, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, November 22, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 22, 2024APPLICATION FILING RECEIPT MAILED
Thursday, January 9, 2025CHANGE OF NAME/ADDRESS REC'D FROM IB
Wednesday, March 26, 2025ASSIGNED TO EXAMINER
Monday, April 7, 2025NON-FINAL ACTION WRITTEN
Tuesday, April 8, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW